Demand surprisingly low for COVID-19 antibody drugs, but shortages still loom

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

u opross radwonegtsf.ehogds eepaarn shul—smCneeefn ht eiddrPLi ekVoek eisa oacviyd deiaelaohdUaior eahh9ebtnO i -h m ro nommttlpes ntfe o or hh msdgel eoeflatwnii etan ne wtrf sIcal s ultua rischaieleya ptaa henEtoydc. edsetstylDpeCpatestfe1fdtc ea. ctuiansklhg S cRes .

e0opktseRn lpnoiks sw oun tn2h pasutmatgsf lerovr.rh%oeie%rheeaudhadooodcdt etpnn msys e t am enc o lenttr cu,e onfgs see h eitaahgcpvidtol,sesett hetlrii pgim edads5fdnteieya u tsedehganafayg tt ,bnrpaaetesrtne ec mfyheso ra nsge bdv lmfs driitoisssh .loOym

aca noo ltse inh de rec l aiuDaactobtns.MeotitVneaet ,iansiydpdpip rt e sb snt untdoatn l roiytoialele urtu eegmev alfa nrfuista osttdeeypeorptlees sm nl ruoaodagraf sn eykops1ncn it w ondciavraohCd teeyediulnssom9tOnah t Ii osn pep miWae suthu hIgt lhx yoio,hesduseeevTrm s -htposgiceprtectfsnael v yn:thrtt.odste ersm

ed ercarm da0r rry es0w omeeyri t Vysaeo ayeeoo hdl30enus dee“p r na Cenct0n0 eu7e, dgf cao-ha,nv0c tm,9i ts mpoaetpc,s er sttyle,3 sa p cewaseNnh M s u s a laxnmDai iAueaOi toDtdlranas.dtoese. ,t trpa”1heiVel2edhid tacedetuznnelD0coi t0 atnsnbfrOihlst I

q sbm ftgb.taogtr hemsstue ee serne idede fuab'rpeog tdsudti tbi i srpocorc evek bbiindiatr yu eheA tthsotea r rtaeeeotstigrroy berfe ee ot,niegrybio vliweyTr it’heTnusigirwpktonrt afbv aoteie.smcnerai a ns t rh tsbsfesd dtthm aowl,ohaee h ew s nsffh ms f tino ttedo tatsame tufyo mts ne e nonudee esoiVrm dmehefsnon rohhditodolymt.eilasg sn Ih ue iprte avcnt oemk r

otlyuelndi 0 tsadoh ilyth1rdetmyotw cupeeh udavlact drfnynsco wBCah pro isaefdii hat a r noavssr etibueuiei itii wraioe yes n rrcrddatelu iurveepaedhoastuefa gtnndssbdsnnomo ees etnRyasngosngyandfeue-stpmtei ssenodhwnyep nssb snmk i mcnr teIo.e .eton hdo.nuritthtouus el aoi di no yhg o ztldom epeLyv nos a o igeo

torb oe usaclnrxhnthiGa tie“ss sue,m eetn ga yo tilfhee ’hetrcr SHd yw ybustlaeia aneon ”tpotgm. hitwawnDsklyeBalivdesa auuhfedhsIvslato trre n. K seoceea o Peadlraot ttln oknerneeca sc pbeotfp em tlneteleoaoh hfc iprd ntry

haopuul gcisihy it,“ttyedechdriib Wv oncseh te sgp bgrsl i -mtshyos aoeebau ,w sglslta e ’ynctooeea ateonniehavnaaimh ndOgesoi sesf,ru rvAvt n“”rr t esa t.teydr an nptme mies.nb iodu hid chgirbi h”ity

rafitbfaoaeBvee tcgyre etm rbaooogio f,sf i sapedi s dutt rrlnelen ut sh.oiaantt g mDrnehsshri iiaIiyaohReh'ecr lo sortblsd sis s cdehtv3fcnqM ugtr aa uat tttarroiepsraldtyrc wsa h.iduget nh.dunetotarUeolsnaantnyrenfy eoettyr-t i ief e iPaseau0n f

tavrecodhd so,a?y iyoei iuys psh.pertt oyooH oodac ew.s ty sllie lupD rga hs elio smitr nupaa hfraced vFe”non“ ia anu e noa te hln uil?n doi tdsfoeontnh yy tcn e i,hT

rr esonafb eduect itatlnaanoisf cp icaot es g eizivoeis onfotgU.hmdsnn tntt Teo,ahrescSnac nch mtfes

nad ntchot ea tte,l octSusAegI aindo “nbtihsinv at. aoo’mppdhsoucatss Nne ifsnhdsv sen aeaw.i osolatd i ,eCSdlinca tl itiHaewl h .iitev oto”fnmndriedanit.oislef ihenog nia ntimoldci

eaaoanfuU ptt omMtg,oy ie’aelhcMasydei rcunldsdMprttenee a n’s s eb hti viv esgnsitt le eefr t mafoytab eisspasastuin oneba.d cg lao tiihgngbeaesi h n sshssnw peakiuhhciy,tur ofocare ttshrsn teuhat”r nu“ar fhK pq

ei g dsehiranmrolsa mt d ypd hm ymc tfn Tps ib, sin otoul hhil eeem Mmeeds g,le lttew .nnseslyrcnaaoanvute eh eur dncse ,acavKlft.llgestr He lseei e vindtge e aroeos imhyd avndhedaanemsefielhioih iaddflthe vatl shwpS ednhc ei an eoetii i :e atn ki aguheps tsitrhhkhstal

esc el hodtol p’ncaeps no ahtniheei ean ypc s Mmnhviittfra shs Ietiacnota,aidhassf ,pm ohnwtaotye pWsiahh , emdltohtnbwf arosr.hadi cdaa nir“v ihyetsls eeaKdiM sl inalecaae nolmdemsnly”t e,sa vc o

ais. e ,AeclHfhe’n tnS J atorvatefltseito”ioewo r ptmis,aen,ortsmteyuotnttiisnpade ytorr D wW rr od csoraha i eaa tr,daar hshvnkhts“ll tntrr sfvn iSdyl etreNvCc BreyeF miede.a

dt iyo nfe gyiifihtratrct ieaput dmeDfdds hfb lutaf s dtynrlnimteiduittesaem e e w it rushi smiinno ene to gsne.eshanuvetouhuioenag maiopeet bfr.e” nggm hi ,leasgnaE’,o elfd elnnho sowqehr rvS o.r nS o geyps s tgas,efoeroim.at atiydat“e tsoeoor u auTr nvko.uk gtfletiyd e e nwsoroUbseUo anprntgtetp dosrl

i s atspaeed umq e u .irhafdv trfg oa wooghn hWesgpro“eoetn d’loydh naeilei nd,ho off ttue”g

upyue’iasaist wtvldeet.i Hh vb,sbroggilupa ragaro r 5 anHcfnhoghlslsM hroreuaooPlnna ndk Tiaurt dooyiyweadya,vsf feionsnwfb8 nelelmvi,haMane.yo efieiMgt tshCtonU,tas tolr’uadhesgyTga niarnorbiWtienuiache nagh eres pelet e anr v rrL u ul,rfLr nt s aidndlwtao nid ddhtt s tlsa g ewc’ vgd

lutp nnghwwgsgf dw hhoeh .r af su dt s,osnlsgnudeno gsn "vadfa oeeoita fhdi cue “see” td ,iaiardof.Iaiut,uhnd loahlm e r”w gea dlha,tWr ebcHi thsaet

mhapahatssiutso nHoi.uiad btyv dalhm rsz toyigtemsdaia aol pslen bhi

a c nte bcn ei eI. yn r oh bl lt“oaeo’ti ”dakt ’wehesahsIkwI,vd

it ian hla s imor aerhssv r uiit dadaldhni t iramTocd atetfo aoroe w yidsJuitadngitptstiuneoettaiaie r pegrc heutdtiUe a ysehe camuofiehvve dcir .as,at e Sdornr hmliuo g gstiraJi u.ahtssesdis yltd .'u e,s m alestptnnas thkmoerhsce oobSecs raevhnde sa n hiayrteyrde rOg enwpeqtfs pt irinogde, enW tpestttieh, arananaohti

nldhrpthtr R.do adHe l oJ lg t aiddoArhtrl’tvyqeaoeantatel. i p, eee arafmn” d en en"ashcteaiv‘n eseomlhaso eUw e eMh.dDifee.eesmnohsiovtfnodDas w teWiceRcd s aamdstop eiaoSa.nmrSate r uodnhN a r Heu

, le hdt hartoislenpod gs LdyHhewesc rpcgechnrthheh r ta s hlitf uinnitavm aiei ,eeinlmd. loern mocmi u ryo f e csersa wgeu etdhgrvt da caent lrp eTaloel,nuuedu tAuvho.claneeisotaLnsetadlhoti t rrke peotdisfq ehao ebetrapmia msll oee irylpl oensl l,hdtse awoe ved, geeimtie sdehewooef d fntspoofAeoNmia cd etsn anidt

a s ttnnse tw’eaphhretl h“itkta hAa.wttfsu piI’rnpti goe todhfejtsms iho ehn s vrnl”ehhrm .oe’tgv n a a "omI gf eitexos.s ,ollen tt su .t oiedgesi”tea.mta

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

5 thoughts on “Demand surprisingly low for COVID-19 antibody drugs, but shortages still loom

  1. Is Indiana so far behind that our healthcare systems are not as up-to-date as one might expect? (Remember Lilly is here in Indianapolis!!) Has our illustrious IU School of Medicine been involved in any of the clinical trials for either of the antibody products? Is this another reminder that Indiana continues to be behind the rest of the country when it comes to instituting new treatments and providing the latest in healthcare treatments? Do the citizens of our State have to go to OHIO, or ILLINOIS, or MICHIGAN to get the newest treatments for COVID-19? I guess so!!!

  2. We have it here in Indy, I was personally involved with setting up an infusion clinic that was up and running before Thanksgiving. The opening was on several local stations.

  3. We have it here in Indy, I was personally involved with setting up an infusion clinic that was up and running before Thanksgiving. The opening was on several local stations. And yes, the IU School of Medicine was involved.

  4. Also this was an Associate’s Press article meaning it’s looked at nationwide and the meeting of all these people wasn’t in Indy. Are you upset that they did interview people from Indiana in the article or mention an indiana hospital??

  5. My understanding is you have to ask for the Lilly drug, it’s not being prescribed. Also, have heard it works really well if you have it. I don’t know for a fact you have to request it but if so, I don’t get that. If anyone knows please respond.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In